Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proxalutamide in Hospitalized COVID-19 Patients (South Proxa-Rescue)
NCT05126628Phase 3Completed
- Sponsor
- Corpometria Institute
- Start
- Mar 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Proxalutamide + Usual Care with Placebo + Usual Care (2 arms). Primary endpoint: 14-Day Recovery Rate. Started Mar 2021; status: completed.
02
Drugs
proxalutamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05126628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126628.